Abstract Details

Title Subcutaneous Daclizumab, Injection-Site Reactions, and Anti-Drug Antibodies: Results from the Phase 2 CHOICE Trial

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 200

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Jacob S. Elkins, MD	No disclosure on file
	No disclosure on file
Varun V. Reddy, MD	No disclosure on file
	No disclosure on file
Katherine A. Riester, MPH (Biogen)	No disclosure on file
Phillip A. Low, MD, FAAN (Mayo Clinic)	Dr. Low has nothing to disclose.

��ɫ��